• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    PepGen Inc. - Common Stock (NQ: PEPG )

    18.00 +1.47 (+8.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 115,080
    Open 16.85
    Bid (Size) 17.71 (1)
    Ask (Size) 18.35 (1)
    Prev. Close 16.53
    Today's Range 16.70 - 18.20
    52wk Range 3.720 - 18.72
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
    From PepGen Inc.
    Via Business Wire
    PepGen Announces Executive Team Promotions
    From PepGen Inc.
    Via Business Wire

    Performance

    YTD
    +153.88%
    +153.88%
    1 Month
    +3.63%
    +3.63%
    3 Month
    +47.18%
    +47.18%
    6 Month
    +171.49%
    +171.49%
    1 Year
    +134.38%
    +134.38%

    More News

    Read More
    PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
    Via InvestorPlace
    PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    From PepGen Inc.
    Via GlobeNewswire
    PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
    Via InvestorPlace
    PepGen: Q3 Earnings Insights
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Insiders Buying GameStop And 2 Other Stocks
    Via Benzinga
    PepGen to Participate in Upcoming Investor Conferences
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
    From PepGen Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
    From PepGen Inc.
    Via GlobeNewswire
    Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
    From PepGen Inc.
    Via GlobeNewswire
    PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
    Via MarketBeat
    Top 4 Health Care Stocks That May Crash This Quarter
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Mary Beth DeLena Joins PepGen as General Counsel and Secretary
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
    From PepGen Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.